Dimensional Fund Advisors LP decreased its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 43.3% in the 4th quarter, Holdings Channel reports. The fund owned 604,043 shares of the company’s stock after selling 461,618 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Teva Pharmaceutical Industries were worth $9,314,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. FMR LLC increased its holdings in Teva Pharmaceutical Industries by 44.0% during the 4th quarter. FMR LLC now owns 35,248,665 shares of the company’s stock worth $543,534,000 after purchasing an additional 10,766,729 shares in the last quarter. Actinver Wealth Management Inc. bought a new position in Teva Pharmaceutical Industries during the 4th quarter worth about $252,000. HighPoint Advisor Group LLC increased its holdings in Teva Pharmaceutical Industries by 10.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 11,885 shares of the company’s stock worth $214,000 after purchasing an additional 1,153 shares in the last quarter. APG Asset Management N.V. increased its holdings in Teva Pharmaceutical Industries by 325.2% during the 4th quarter. APG Asset Management N.V. now owns 613,585 shares of the company’s stock worth $8,277,000 after purchasing an additional 469,295 shares in the last quarter. Finally, HRT Financial LLC bought a new position in Teva Pharmaceutical Industries during the 4th quarter worth about $547,000. Institutional investors own 65.10% of the company’s stock.

In related news, VP Notaristefani Carlo De sold 16,070 shares of the firm’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $11.42, for a total value of $183,519.40. Following the completion of the sale, the vice president now directly owns 49,659 shares in the company, valued at approximately $567,105.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sol J. Barer bought 111,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was purchased at an average price of $8.98 per share, with a total value of $996,780.00. Following the completion of the purchase, the director now directly owns 115,942 shares in the company, valued at approximately $1,041,159.16. The disclosure for this purchase can be found here. Insiders sold a total of 18,860 shares of company stock valued at $226,854 over the last quarter. 0.49% of the stock is currently owned by company insiders.

TEVA has been the subject of a number of research reports. Mizuho cut Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $25.00 to $18.00 in a report on Wednesday, February 20th. Citigroup lowered their target price on Teva Pharmaceutical Industries from $27.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, April 11th. BMO Capital Markets initiated coverage on Teva Pharmaceutical Industries in a report on Thursday, March 28th. They set a “market perform” rating and a $18.00 target price for the company. Wells Fargo & Co reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Friday, May 10th. Finally, Morgan Stanley set a $16.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, May 3rd. Five research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries currently has a consensus rating of “Hold” and a consensus target price of $17.05.

Teva Pharmaceutical Industries stock opened at $8.71 on Thursday. Teva Pharmaceutical Industries Ltd has a one year low of $8.25 and a one year high of $25.96. The company has a debt-to-equity ratio of 1.66, a current ratio of 0.96 and a quick ratio of 0.62. The stock has a market cap of $9.42 billion, a PE ratio of 3.11, a price-to-earnings-growth ratio of 1.12 and a beta of 1.65.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.57 EPS for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The company had revenue of $4.30 billion during the quarter, compared to the consensus estimate of $4.38 billion. During the same period in the prior year, the business posted $0.94 EPS. The company’s quarterly revenue was down 15.2% on a year-over-year basis. On average, sell-side analysts expect that Teva Pharmaceutical Industries Ltd will post 2.26 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://theolympiareport.com/2019/06/13/dimensional-fund-advisors-lp-sells-461618-shares-of-teva-pharmaceutical-industries-ltd-nyseteva.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: What is Cost of Debt?

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.